Safety and Efficacy of the Visual Field Improvement After Selective Intra-arterial Thrombolysis for Central Retinal Artery Occlusion
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 128
- 试验地点
- 1
- 主要终点
- Change of the visual field index as visual field index (VFI) examed by Humphrey visual field analyzer at 3 months
研究概览
简要总结
Central retinal artery occlusion (CRAO) is an ophthalmic emergency which leads to devastating visual function defects and poor prognosis. Though traditional conservative treatments are widely used, none of them is proved to be effective. A number of meta-analyses and observational studies indicate intravenous thrombolysis to be beneficial in CRAO. Selective intra-arterial thrombolysis (IAT) introducing rt-PA directly into the ophthalmic circulation by super-selective microcatheterization may reduce the complications such as intracranial and systemic hemorrhage.The residual visual field is significant for patients with CRAO who have poor central visual acuity. Thus, it is clinically significant to study the changes in visual fields in eyes with CRAO.
详细描述
Central retinal artery occlusion (CRAO) is an ophthalmic emergency which leads to devastating visual function defects and poor prognosis. Though traditional conservative treatments are widely used, none of them is proved to be effective. The respective responses of brain and retinal tissues to acute ischemia share many features is the rationale for therapeutic thrombolysis in CRAO. Intravenous thrombolysis (IVT) has been a therapeutic choice for CRAO since the 1960s, and in the United States, tPA is currently administered in 5.8% of patients admitted with CRAO. A number of meta-analyses and observational studies indicate intravenous thrombolysis to be beneficial in CRAO. Selective intra-arterial thrombolysis (IAT) introducing rt-PA directly into the ophthalmic circulation by super-selective microcatheterization which has the advantage of reducing the dose of rt-PA reaching the systemic circulation. Thus, IAT may reduce the complications such as intracranial and systemic hemorrhage. The residual visual field is significant for patients with CRAO who have poor central visual acuity. Thus, it is clinically significant to study the changes in visual fields in eyes with CRAO. Sequential evaluation by Humphrey perimetry will evaluate the temporal changes before and after IAT or conservative therapies. Our study will enroll patients within 7 days of symptom onset and aims at evaluating the safety of IAT and comparing the improvement of the VFDs between conservative treatments and IAT combined with conservative treatments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Non-arteritic CRAO with symptom duration ≤7d
- •Age from 18 years old between 80 years old
- •Qualified systemic conditions, well-controlled blood pressure, well-controlled blood glucose, qualified liver and kidney function, no allergic history to contrast agent or rt-PA,
- •Meet the inclusion of HBOT
排除标准
- •Ocular factor or disease
- •Branch retinal artery occlusion
- •Combined retinal vein occlusion
- •Suspicious ocular ischemic syndrome, such as ophthalmic artery occlusion or carotid artery occlusion
- •Existed retinal problems decreasing visual function, such as macular disease, severe nonproliferative or proliferative diabetic retinopathy, severe cataract or glaucoma
- •Central retinal artery occlusion from iatrogenic cause
- •History of thrombolysis for CRAO or CRVO
- •Systemic factors restricting thrombolysis
- •Uncontrolled hypertension (systolic blood pressure > 180mmHg ); Uncontrolled hyperglycemia (fasting blood glucose > 9mmol/L);
- •Coagulation disorder
- •History of intracranial hemorrhage, heart attack, cerebral infarction, or intracranial surgery within 3 mo
- •Current antithrombotic treatment
- •History of allergic reaction to contrast agent or rt-PA
结局指标
主要结局
Change of the visual field index as visual field index (VFI) examed by Humphrey visual field analyzer at 3 months
时间窗: 90 days
Change of the visual field index
Change of the visual field index as mean deviation (MD) examed by Humphrey visual field analyzer at 3 months
时间窗: 90 days
Change of the mean deviation
次要结局
- Change of Best corrected visual acuity (BCVA) at 3 months(90 days)
- Adverse reactions at 1 month(30 days)
研究者
Ping Fei
Associate professor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
